PT  - JOURNAL ARTICLE
AU  - Wilfong, Erin M.
AU  - Bartkowiak, Todd
AU  - Vowell, Katherine N.
AU  - Westlake, Camille S.
AU  - Irish, Jonathan M.
AU  - Kendall, Peggy L.
AU  - Crofford, Leslie J.
AU  - Bonami, Rachel H.
TI  - High-dimensional analysis reveals abnormal B cell subsets associated with specific changes to circulating T and myeloid cell populations in patients with idiopathic inflammatory myopathies
AID  - 10.1101/2021.03.23.21253635
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.23.21253635
4099  - http://medrxiv.org/content/early/2021/03/26/2021.03.23.21253635.short
4100  - http://medrxiv.org/content/early/2021/03/26/2021.03.23.21253635.full
AB  - Objectives The idiopathic inflammatory myopathies (IIM) are a clinically heterogeneous group of conditions affecting the skin, muscle, joint, and lung in various combinations. This study aims to investigate the immunologic heterogeneity through detailed immunophenotyping of peripheral blood mononuclear cells (PBMCs) in IIM patients and healthy controls.Methods We collected PBMCs from 17 patients with a clinical diagnosis of inflammatory myositis in the inpatient or outpatient setting and performed immunophenotyping using mass cytometry by time of flight (CyTOF) to simultaneously characterize B, T, and myeloid cell subsets. Data were analyzed using a combination of supervised biaxial gating and unsupervised clustering algorithms including t-distributed stochastic neighbor embedding (tSNE), cluster identification, characterization, and regression (CITRUS), and marker enrichment modeling (MEM).Results We identified two distinct immune signatures amongst IIM patients. In one signature, increased CD19+CXCR4hiCCR7hi cells correlated with increased CD3+CXCR4hiCD38hi (r=0.62, p=0.009) and CD14+CD16-CXCR4+CD38+HLADR-(r=0.61, p=0.01) populations. In the second signature, increased CD19+CD21loCD11c+ cells correlated with an increased CD3+CD4+PD1+ (r=0.60, p=0.01) population. Other shared immunologic features amongst IIM patients compared to healthy controls included decreased surface expression of RP105/CD180 on B cells (median mass intensity 39.9 ± 16.0 v. 60.9 ± 20.1, p=0.002). In the T cell compartment, all circulating CD3+CXCR3+ subsets (2.7 ± 2.4 v. 9.6 ± 8.1% of all PBMCs, p=0.0004) were reduced.Conclusion Based on circulating B cell phenotype, we identified two distinct immunologic signatures in IIM patients. Future work is needed to determine the significance of these immune signatures for clinical manifestations and treatment responses.Competing Interest StatementEMW receives research funding from Boehringer-Ingelheim and is a member of their myositis ILD advisory board. JMI was a co-founder and a board member of Cytobank Inc. and has engaged in sponsored research with Incyte Corp, Janssen, Pharmacyclics. No other author reports a competing interest.Funding StatementThis work was supported by CTSA award No. UL1TR000445 (EMW, LJC) from the National Center for Advancing Translational Sciences, the National Institutes of Health T32HL087738 (EMW), KL2TR002245 (EMW), K12HD043483 (RHB), T32AR0590139 (JJY), K00-CA212447 (TB), R01 CA226833 (JMI), U54 CA217450 (JMI), The Myositis Association (EMW), Myositis UK (EMW), Vanderbilt Faculty Research Scholars Award (EMW), Vanderbilt Human Immunology Discovery Initiative, and the Porter Family Fund for Autoimmunity Research. The contents are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:VUMC IRB 141415All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is included in either the main manuscript or supplemental materials.(ARS)anti-tRNA synthetase syndrome(BCR)B cell receptor(CITRUS)cluster identification, characterization, and regressionILD)interstitial lung disease(CyTOF)mass cytometry by time of flight(IIM)idiopathic inflammatory myopathies(MEM)marker enrichment modeling(MHCII)major histocompatibility complex class II(MFI)Median Mass Intensities(MMI)mean fluorescence intensity(PBMCs)peripheral blood mononuclear cells(tSNE)t-distributed stochastic neighbor embedding